Skip to content
lifestyle.californiaconsumerbanking.com
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
ACCRO BIOSCIENCE
Accro Bioscience Announces First Patient Dosed in Phase IIb Study of AC-101 in Moderate-to-Severe Ulcerative Colitis
September 20, 2026
Accro Bioscience Announces Inclusion of AC-101 tablets in the NMPA CDE’s “Caring Plan-Extension” Pilot Program for Rare Disease Drug Development
September 13, 2026
AC-201 for Vitiligo: Accro Bioscience Secures IND Clearance for Trials
September 8, 2026
Accro Bioscience to Present Phase Ib Data of AC-101, an Oral Selective RIPK2 Inhibitor, for Moderate-to-Severe UC at UEG Week 2026 in Barcelona
August 13, 2026
Accro Bioscience Announces $50 Million Series C Financing Led by OrbiMed to Advance Clinical Pipeline for Immune Mediated Diseases
May 18, 2026